Editorial Perspectives on CGT Cold Chain Logistics

1. Arcellx On Designing A Dynamic CAR-T 3/13/2025

   Arcellx's CMO and CTO talk about the company's platform technology, its partnership with Kite, and preparing its lead asset, anito-cel, for commercial launch.

2. Allogene's Mission To Democratize CAR-T 11/22/2024

   Allogene Therapeutics CEO and co-founder, David Chang, MD, Ph.D., talks about the exciting future of allogeneic CAR-T and shares the company's mission to bring these therapies to patients.

3. Highlights From ARM's 2024 Meeting On The Mesa 10/25/2024

   ARM's 2024 Meeting on the Mesa has concluded. Here are a few brief highlights from this year's conference.

4. Using Stem Cells As An Immunologic 'Trojan Horse' 5/23/2024

   The immune system makes therapeutic delivery challenging, even for immunotherapies. Learn how Calidi Biotherapeutics is using stem cells to sneak oncolytic viruses past the immune system to the sites of solid tumors.

5. Do ClinOps Professionals Understand The CAR-T Supply Chain? 3/4/2024

   Lee Clough RN, HP, of Novartis talks about the importance of understanding the nuances associated with collecting and shipping autologous material (i.e., CAR-Ts) for clinical trials. 

6. My Top Editorial Picks for 2022 12/19/2022

   Fair warning, Cell & Gene readers. While this list includes some of my favorite editorial from 2022, it’s not even remotely close to being as extensive as I’d like. Why is that? Our library of content is so deep and so rich, I couldn’t possibly share and recap all of it with you in one article. Here are some highlights that helped to inform our readers about everything from process development to vendor selection to partnering with the right investment team.

7. The Placental Stem Cell Advantage 5/11/2021

   As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research into practice. Could the production platform it’s building be the key to accessible, affordable allogeneic cell therapy?

8. Manufacturing Facility Will Meet Needs Of Cell & Gene Trials 5/14/2019

   Abeona Therapeutics is developing investigational gene and cell therapies for people living with serious and rare diseases. Last year, Abeona held a ribbon-cutting ceremony to celebrate the groundbreaking of a manufacturing facility that is one year later producing gene therapy material for their clinical and pre-clinical programs. As is the norm with gene therapy, Abeona uses a virus as vehicles to deliver functional copies of defective genes.

9. Sneak Peek: The Unique Challenges Of Cell And Gene Supply Chains 1/22/2019

   Two of the field’s most valuable luminaries representing both academia and industry — Dr. Bruce Levine and Simon Ellison, ISCT Commercialization Committee — discuss determining how CMOs can and should successfully manage cell and gene therapy supply chains.

10. Are Your Cell Therapy Samples Getting The Preservation They Deserve? 1/17/2017

    With the number of biologics now in development and soon to be making their way into clinical trials, the preservation of cells, tissues, and organs are suddenly increasing in importance. Companies handling the manufacturing, storage, and transportation of these materials need to be focused on improving the yield and extending the shelf life of these time and temperature sensitive biologics.